great results, page-6

re: srx news american journal of oncology Access to American Journal of Oncology and Hematology featured article just coming out has widepread implications in treatment regimen as standard of care in treatment with adjuvant therapy for metastaic disease to the liver with newer generation chemotherapy drugs from any of five Sirtex parners. The market potential from this and the successful launching of Sir Spheres to the one billion Chinese eligible patient population even with a one per cent penetrance would produce several hundred million dollars of revenue in next couple of years. Hunter Hall originally predicted $19 share price for Sir Spheres when bid was rejected by Sirtex from Cephalon in 2003. Now they are saying they think they were just wrong on their timing by three years but their price target is very much higher than current $2.90. My opinion only (and HH) and do your own work. Goodday mates. Also alot of conferences and presentions with excellent trial results being reported in journals coming up to expand indications which is another revenue stream for the company.